Delphi

The Delphi program aims to develop modular wearable or ingestible sensors for monitoring a broad range of biological markers, such as hormones, cytokines, and drug levels. The program will leverage chiplets, a new system architecture in microelectronics, to decrease cost, reduce size, weight, and power, and enable all developers to access cutting-edge capabilities. The benefits of this program include early detection to prevent disease progression, continuous monitoring for safe home recovery, and precision, closed-loop monitoring of therapies for superior outcomes. • The program will focus on the development of chiplets for biosensing, including ultra-low power management and secure communication of medical data. • The program will also focus on the development of biocompatible packages for the chiplets, which must be fully encapsulated except at the sensing interface. • The program will require the development of modular wearable or ingestible sensors that can monitor a broad range of biological markers. • The program will prioritize awards to entities that conduct funded work in the United States, but foreign entities may participate if they comply with non-disclosure agreements, security regulations, export control laws, and other governing statutes.